Should DNA analysis be performed for a patient with ambiguous hemoglobin electrophoresis or HPLC results to differentiate HbE trait, homozygous HbE, and HbE/β‑thalassemia?

DNA Analysis is Essential for Ambiguous HbE Cases

Yes, DNA analysis should be performed when hemoglobin electrophoresis or HPLC results cannot definitively differentiate between HbE trait, homozygous HbE, and HbE/β-thalassemia, as these conditions have overlapping phenotypes but vastly different clinical implications for morbidity and quality of life.

Why DNA Analysis is Critical

The fundamental problem is that HbE-β⁺-thalassemia can present with an Hb phenotype identical to simple HbE heterozygosity, particularly when HbF levels are low 1. This creates a diagnostic trap with serious consequences:

• HbE-β⁺-thalassemia patients may be misdiagnosed as simple HbE carriers, leading to inadequate monitoring and genetic counseling
• The clinical severity differs dramatically: HbE trait is benign, while HbE/β-thalassemia can range from mild to transfusion-dependent anemia
• Protein-based methods (HPLC, electrophoresis) alone cannot reliably distinguish these genotypes 2

When to Order DNA Analysis

Order DNA analysis in the following scenarios:

1. HbE level ≥35.0% on HPLC - This cutoff has 100% sensitivity and specificity for identifying HbE-β⁺-thalassemia that requires DNA confirmation 1. Levels below 35% suggest compound heterozygosity rather than simple trait.

2. Elevated HbA2 (≥3.6%) AND/OR elevated HbF (≥5.0%) in patients with HbE patterns - These findings increase the odds of misinterpretation 7-18 fold 3. The combination of both abnormalities raises the error rate to 71.9%.

3. Discordant hematological indices - Marked microcytosis (MCV <70 fL) with disproportionately high RBC count suggests compound conditions requiring molecular clarification 4.

4. Family planning or prenatal counseling - When accurate carrier status determination affects reproductive decisions, DNA analysis is mandatory 2.

What DNA Analysis Should Include

The molecular workup must be comprehensive:

• β-globin gene sequencing to identify the specific β-thalassemia mutation (common mutations include β-87(C>A), β-31(A>G), β-28(A>G), β-19(A>G), and β-126(T>G)) 1
• α-globin gene analysis - Critical because 46.3% of HbE-β⁺-thalassemia patients with low HbF have co-inherited α-thalassemia, which modifies the phenotype 1
• XmnI polymorphism testing at -158 nt 5' to Gγ-globin - This modifies HbF expression and affects clinical presentation 1

Common Pitfalls to Avoid

Do not rely solely on HPLC or capillary electrophoresis when HbE is present. While these methods accurately quantify hemoglobin fractions, they cannot determine the underlying genotype 3, 5.

Do not assume normal HbA2 and HbF exclude compound conditions. Some HbE-β⁺-thalassemia patients present with minimally elevated or even normal HbF levels due to co-inherited α-thalassemia or unfavorable XmnI polymorphisms 1.

Always perform α-thalassemia screening in confirmed HbE-β⁺-thalassemia cases, as this significantly impacts phenotype severity and genetic counseling 1.

Clinical Algorithm

1. Perform HPLC or capillary electrophoresis as initial screening
2. If HbE pattern detected, measure HbE level precisely
3. If HbE ≥35% → Proceed directly to DNA analysis 1
4. If HbE <35% with HbA2 ≥3.6% or HbF ≥5.0% → DNA analysis recommended 3
5. If DNA confirms HbE-β-thalassemia → Add α-globin gene analysis 1
6. Use combined genotype data for accurate prognosis and counseling

The cost of DNA analysis is justified by preventing misdiagnosis of a potentially significant hemoglobinopathy as a benign carrier state, which has implications for patient monitoring, family screening, and reproductive counseling 2.